Tiba Biotech receives a Phase I SBIR grant from NIAID to develop a multi-antigen RNA-based vaccine against the highly pathogenic H7N9 strain of influenza virus.
Today Tiba was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health. In response to an earlier Notice of Special Interest, this six-month grant is to develop an RNA-based multi-antigen vaccine for SARS-CoV-2.
Today Tiba was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health. In response to an earlier Notice of Special Interest, this six-month grant is to develop an RNA-based multi-antigen vaccine for SARS-CoV-2.
Today Tiba was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health. In response to an earlier Notice of Special Interest, this six-month grant is to develop an RNA-based multi-antigen vaccine for SARS-CoV-2.
© 2024 Tiba Biotech LLC. All rights reserved
Keep connected with us
Terms and Conditions
